Improving the quality of biomarker discovery research: The right samples and enough of them

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 6, 2015, Pages 944-950

  Pepe, Margaret S ^a   Li, Christopher I ^a   Feng, Ziding ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; CANCER SCREENING; COLON CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); FOLLOW UP; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY CONTROL; RECURRENCE RISK; SAMPLE SIZE; STUDY DESIGN; COHORT ANALYSIS; COLONIC NEOPLASMS; HUMAN; MEDICAL RESEARCH; METABOLISM; METHODOLOGY; PROGNOSIS; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; BIOMEDICAL RESEARCH; COHORT STUDIES; COLONIC NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84941797534     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1227     Document Type: Article

References (16)

1. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52.
2. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson M, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
3. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432-8.
4. Wallstrom G, Anderson KS, LaBaer J. Biomarker discovery for heterogeneous diseases. Cancer Epidemiol Biomarkers Prev 2013;22:747-55.
5. Skates SJ, Gillette MA, LaBaer J, Carr SA, Anderson L, Liebler DC, et al. Statistical design for biospecimen cohort size in proteomics-based discovery and verification studies. J Proteome Res 2013;12:5383-94.
6. Pepe MS, Longton G, Anderson GL, Schummer M. Selecting differentially expressed genes frommicroarray experiments. Biometrics 2003;59:133-42.
7. Li SS, Bigler J, Lampe JW, Potter JD, Feng Z. FDR-controlling testing procedures and sample size determination for microarrays. Stat Med 2005;24:2267-80.
8. Tibshirani R. A simple method for assessing sample sizes in microarray experiments. BMC Bioinformatics 2006;7:106.
9. Fuzery AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013;10:13.
10. Baker SG. Improving the biomarker pipeline to develop and evaluate cancer screening tests. J Natl Cancer Inst 2009;101:1-4
11. Baker SG, Kramer BS. Usingmicroarrays to study themicroenvironment in tumor biology: the crucial role of statistics. Semin Cancer Biol 2008; 18:305-10.
12. Feng Z. Classification versus association models: should the samemethods apply? Scand J Clin Lab Invest 2010;70(Suppl 242):53-8.
13. Dobbin K, Simon R. Sample size determination inmicroarray experiments for class comparison and prognostic classification. Biostatistics 2005;6: 27-38.
14. Pepe MS. The statistical evaluation of medical tests for classification and prediction. Oxford: Oxford University Press; 2003.
15. Dobbin KK, Simon RM. Sample size planning for developing classifiers using high-dimensional DNA microarray data. Biostatistics 2007;8: 101-17.
16. Feng Z, Prentice RL, Srivastava S. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 2004;5:709-19.